ISSN 1662-4009 (online)

ey0021.10-3 | Clinical Trials – New Treatments | ESPEYB21

10.3. Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial

L Krogvold , IM Mynarek , E Ponzi , FB Mork , TW Hessel , T Roald , al. et

Brief Summary: The Diabetes Virus Detection (DiViD) Intervention phase 2, placebo-controlled, double-blind trial randomized 96 children and adolescents (age 6-15 years) with new-onset type 1 diabetes (T1D) to receive either the antivirals, Pleconaril and Ribavirin, (n=47) or placebo (n=49) for 6 months. The antiviral treatment improved β-cell function at 12 months, and it was well tolerated and safe.Viral infections, particularly enteroviruses, have...